Un articulo interesante que pone de manifiesto las relaciones entre investigación y negocio.

Un caso flagrante de conflicto de intereses.

DUBLIN, Ireland--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/9a0ef4/cns_drug_discoveri) has announced the addition of the "CNS Drug Discoveries: Parkinson's Disease Chapter" report to their offering.

This chapter of CNS Drug Discoveries focuses on the Parkinson’s disease market.

In 2007, approximately US$3.6 billion was spent on the symptomatic treatment of Parkinson’s disease (PD). Although this neurodegenerative disease affects approximately 1% of the population its prevalence increases with age, thus it is likely to become more commonplace due to patient demographics and become a greater burden to healthcare payers.

PD patients are treated with a cocktail of drugs which are adapted to the patients' needs as the disease progresses. There is no cure and current therapies are relatively effective at treating the symptoms in the early stages but less so in advanced PD, and there remain significant side effects.

Whilst generic levodopa remains the cornerstone of treatment and is widely available relatively cheaply, its chronic use is not necessarily limited by budget, but by its long-term effectiveness. Hence, the more costly dopamine agonists have gained utility in the treatment of the early stage of the disease helping to spare levodopa treatment.

However, over the next six years many of the leading dopamine agonists face patent expiration, enabling generics to become more freely available. Meanwhile some companies have new improved dopamine agonists in their pipelines such as Solvay’s pardoprunox or more potent monoamine oxidase inhibitors such as Merck KGaA/Newron's safinamide.

Some companies have picked up the gauntlet and run to develop new disease-modifying agents which could revolutionise the way advanced PD is treated. For example, Bayer's high-risk, high-reward approach to developing spheramine is a novel cell therapy that may halt the progression of PD.

Key PD questions answered include:

• What percentage of the treatable population for PD has been diagnosed in Europe, US and Japan?
• Which PD products will face generic challenges by 2014?
• What are the commercial prospects for Bayer’s revolutionary disease-modifying agent spheramine?
• By 2014, Boehringer Ingelheim and GSK will have lost considerable PD market share - to whom and what products will make the difference?

Key Products Analysed and Forecast:

• Apokyn - Britannia/Ipsen
• Azilect - Lundbeck/Teva Pharmaceuticals
• Comtan franchise - Novartis/Orion
• Istradefylline - Kyowa Hakko
• Mirapex - Boehringer Ingelheim
• Neupro - UCB
• Pardoprunox - Solvay
• Requip - GlaxoSmithKline

For more information visit http://www.researchandmarkets.com/research/9a0ef4/cns_drug_discoveri

Source: Espicom Business Intelligence Ltd

Contact:

Research and Markets
Laura Wood
Senior Manager
  Esta dirección electrónica esta protegida contra spam bots. Necesita activar JavaScript para visualizarla
 
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716

Rascol O, Poewe W, Lees A, Aristin M, Salin L, Jul N, et al.

Arch Neurol 2008; 65: 577-583

Se ha demostrado que la tesofensina, un inhibidor de la recaptación de monoamina, tiene algunos efectos beneficiosos en pacientes con la enfermedad de Parkinson en estado avanzado, según un nuevo estudio piloto que ha sido publicado en la revista Archives of Neurology.

Este análisis lo han realizado investigadores franceses sobre 254 pacientes que recibieron aleatoriamente un tratamiento con tesofensina en dosis crecientes desde 0,125 a 1 mg/día o bien un placebo.

Tras 14 semanas de tratamiento con 0,5 mg de tesofensina se observó una diferencia de 4,7 puntos de la subescala para la función motora y para actividades diarias perteneciente a la Unified Parkinson Disease Rating Scale (UPDRS), al compararlos con los resultados obtenidos con el placebo. Con el aumento de la dosis del fármaco, también se observó como aumentaba la concentración plasmática, pero no existía una clara relación dosis-respuesta, además de que con el aumento de la dosis se aumentaba la cantidad de efectos adversos.